Tempus AI, Inc. (TEM)
Automate Your Wheel Strategy on TEM
With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEM
- Rev/Share 5.4907
- Book/Share 1.7854
- PB 45.2045
- Debt/Equity 2.7563
- CurrentRatio 1.5406
- ROIC -0.1583
- MktCap 13614466996.0
- FreeCF/Share -0.4017
- PFCF -195.4978
- PE -70.0611
- Debt/Assets 0.525
- DivYield 0
- ROE -1.0712
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEM | H.C. Wainwright | -- | Buy | -- | $90 | Sept. 2, 2025 |
| Initiation | TEM | BTIG Research | -- | Buy | -- | $60 | April 21, 2025 |
| Downgrade | TEM | JP Morgan | Overweight | Neutral | $50 | $55 | Feb. 25, 2025 |
| Downgrade | TEM | William Blair | Outperform | Market Perform | -- | -- | Feb. 12, 2025 |
| Resumed | TEM | TD Cowen | -- | Buy | $58 | $74 | Feb. 5, 2025 |
| Initiation | TEM | Wolfe Research | -- | Outperform | -- | $60 | Dec. 13, 2024 |
| Initiation | TEM | Guggenheim | -- | Buy | -- | $74 | Dec. 9, 2024 |
| Downgrade | TEM | BofA Securities | Buy | Neutral | $45 | $60 | Oct. 2, 2024 |
News
Levi & Korsinsky Investigating Whether Tempus AI, Inc. (TEM) Misled Investors - Securities Law Violations Possible
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Tempus AI, Inc. (TEM)
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
Read More
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.
Read More
Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
Read More
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It.
Read More
Lost Money on Tempus AI, Inc. (TEM)? Possible Fraud - Contact Levi & Korsinsky Today
Published: June 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
Read More
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
Published: June 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / WHY: New York, N.Y., June 1, 2025.
Read More
Levi & Korsinsky Investigates Tempus AI, Inc. (TEM) Over Potential Securities Fraud Allegations
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
Read More
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Tempus AI Inc. (NASDAQ: TEM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., May 30, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Tempus AI, Inc. (NASDAQ: TEM), resulting from allegations of providing potentially misleading business information to the investing public.
Read More
Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
Published: May 30, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. So What: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ATTENTION TEM Shareholders: Lost Money on Tempus AI, Inc.? Contact Levi & Korsinsky About Investigation
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
Read More
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.
Read More
Tempus AI, Inc. Investors: Company Investigated by the Portnoy Law Firm
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King' (UPDATED)
Published: May 29, 2025 by: Benzinga
Sentiment: Negative
Editor's note: This story has been updated to include a statement from a Tempus AI spokesperson.
Read More
TEM Investor Notice: Levi & Korsinsky Investigates Tempus AI, Inc. for Securities Law Violations
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tempus AI, Inc. (TEM) And Encourages Stockholders to Reach Out
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
Read More
Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King'
Published: May 28, 2025 by: Benzinga
Sentiment: Negative
Spruce Point Capital Management has announced a new short position against Tempus AI Inc. TEM. On Wednesday, the short seller raised concerns about the company's management team.
Read More
Tempus AI: Firing On All Cylinders
Published: May 25, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues 32% YoY, but headline growth topped 75% due to the Ambry deal, though organic growth analysis is crucial for investors. The stock trades at a reasonable 7x '26 sales with 25-28% pro forma growth, but limited adjusted EBITDA targets may cap the valuation premium.
Read More
These Investors Search for ‘Extreme Winners.' Why Aurora, BYD, Tempus AI Make the Cut.
Published: May 23, 2025 by: Barrons
Sentiment: Positive
Lingotto Innovation's James Anderson and Morgan Samet favor companies with explosive growth potential and a focus on innovation.
Read More
Tempus AI: I Believe In The Company's Cause
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Positive
I initiate coverage of Tempus AI, Inc. with a Buy rating, driven by its unique data assets and AI-powered oncology solutions. The company posted strong revenue growth and margin expansion, though profitability and high debt remain concerns as it integrates recent acquisitions. Tempus AI's vast clinical and molecular data, validated at major conferences, positions it as a key partner for leading pharma and healthcare companies.
Read More
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL. Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcast of the presentation will be available here. About Tempus Tempus is a technology company advancing precision medicine throug.
Read More
Tempus: Is This Ultra-Fast-Growing Company A Good Investment?
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; organic growth remains strong, but future growth may slow post-acquisition. The company benefits from exposure to large, expanding markets and leverages AI/data partnerships, but faces high valuation multiples.
Read More
These 3 AI-Related Stocks Crushed Earnings
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Earnings season continues to move rapidly, with many companies unveiling quarterly results daily. So far, the period has been positive, though it's worth noting that estimates for the current period (Q2) have trickled lower in recent weeks.
Read More
Big Earnings Beats: 6 Stocks That Spiked After Reporting Results
Published: May 13, 2025 by: 24/7 Wall Street
Sentiment: Neutral
We're winding down earnings season, and the old Wall Street adage that “earnings drive stock prices” continues to prove true.
Read More
These AI Stocks Posted Robust Results: Time to Buy?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings.
Read More
Tempus AI Stock: Time to Double Down or Cut and Run?
Published: May 08, 2025 by: MarketBeat
Sentiment: Positive
Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance.
Read More
Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. (NASDAQ:TEM ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Liz Krutoholow – Vice President-Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Ryan MacDonald – Needham & Company Mark Schappel – Loop Capital Subbu Nambi – Guggenheim Daniel Brennan – TD Cowen Mark Massaro – BTIG Michael Ryskin – Bank of America Rachel Vatnsdal – JPMorgan Dan Arias – Stifel Operator Good day everyone. And thank you for standing by.
Read More
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect
Published: May 06, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today.
Read More
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the T.
Read More
About Tempus AI, Inc. (TEM)
- IPO Date 2024-06-14
- Website https://www.tempus.com
- Industry Medical - Healthcare Information Services
- CEO Eric P. Lefkofsky
- Employees 2400